<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389112</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/3</org_study_id>
    <nct_id>NCT04389112</nct_id>
  </id_info>
  <brief_title>Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions</brief_title>
  <acronym>MITOSKIN</acronym>
  <official_title>Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin carcinomas are the most frequent cancers in the world, including basal cell carcinomas
      and cutaneous squamous cell carcinoma (cSCCs), with more than 60.000 new annual cases in
      France. Their incidence increases mainly due to ultraviolet (UV) exposure and population
      ageing. Then from 1994 to 2006, the incidence of cSCC has increased by 300%. CSCCs typically
      manifests as a spectrum from a precursor actinic keratosis (AK) - possible spontaneous
      regression at this stage- to in situ cSCC invasive cSCC and finally metastatic cSCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although growing evidence indicates that bioenergetic metabolism plays an important role in
      the progression of tumorigenesis, little information is available on the contribution of
      reprogramming of energy metabolism in cancer initiation and how it influences further the
      bioenergetic behavior of tumors.

      By applying a quantitative proteomic approach, the consortium has recently found that
      specific metabolic modifications precede cSCC.

      This study will investigate the role of energy metabolism in malignant transformation of
      premalignant skin lesions into cSCC, and in cSCC progression, with correlation with clinical
      characteristics and metastatic outcomes. Using several cutting-edge technologies in human
      samples, the team will evaluate whether targeting energy metabolism has the potential to be
      used as curative treatments for cSCC and whether pre-determined metabolic alterations could
      be exploited as new preventive strategies. These modifications in energy metabolism could be
      used as prognostic and diagnostic biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who have a glycolysis profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))</measure>
    <time_frame>Day 1</time_frame>
    <description>Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who have an oxidative profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))</measure>
    <time_frame>Day 1</time_frame>
    <description>Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of skin differentiation markers</measure>
    <time_frame>Day 1</time_frame>
    <description>% of samples in each category (AK, in situ, ...) that present differentiation features are assessed by immunostaining of loricrin, filaggrin, K10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of cSCC aggressiveness markers</measure>
    <time_frame>Day 1</time_frame>
    <description>% of samples expressing aggressive markers will be assessed by evaluating the proliferation index, degree of differentiation, invasion beyond subcutaneous fat, perineural invasion, vascular invasion level of infiltration following immunohistochemistry analyses on formalin-fixed paraffin-embedded tissue sections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of skin apoptotic markers</measure>
    <time_frame>Day 1</time_frame>
    <description>% of samples with high apoptotic cell death level will be assessed by immunostaining using antibody against cleaved caspase-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of mitochondrial metabolism on skin biopsies</measure>
    <time_frame>Day 1</time_frame>
    <description>% of samples with high mitochondrial activity will be evaluated by comparing oxygen consumption rate by different fresh samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of cancer proliferative features on skin biopsies</measure>
    <time_frame>Day 1</time_frame>
    <description>% of samples that are highly proliferative will be calculated by measuring the ability of colony formation (SRB Test) and cell cycle progression (flow cytometer, western).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <condition>Basal Cell Carcinomas</condition>
  <arm_group>
    <arm_group_label>Patients with actinic keratoses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with squamous cell carcinoma in situ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with squamous cell carcinomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patient with invasive metastates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.</description>
    <arm_group_label>Patients with actinic keratoses</arm_group_label>
    <arm_group_label>patient with invasive metastates</arm_group_label>
    <arm_group_label>patients with squamous cell carcinoma in situ</arm_group_label>
    <arm_group_label>patients with squamous cell carcinomas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Every patient with suspected lesion :

               -  AK,

               -  in situ cSCC,

               -  infiltrative cSSC

               -  cSCC with recurrent disease

               -  cSCC with cutaneous metastases.

          -  Patients 18 years of age or older,

          -  Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic),

          -  Patient able to sign a consent form,

          -  Patient affiliated with a Social Security system.

        Exclusion Criteria:

          -  Prior systemic treatment such as checkpoint inhibitors or chemotherapy.

          -  Patients with cSCC or AK localized on visible zone of the face or folds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie BEYLOT-BARRY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie BEYLOT-BARRY, MD, PhD</last_name>
    <phone>+335 57 82 25 00</phone>
    <email>marie.beylot-barry@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Léa DOUSSET, MD</last_name>
    <phone>+335 57 82 25 00</phone>
    <email>lea.dousset@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Saint-André - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie BEYLOT-BARRY, MD, PhD</last_name>
      <phone>+335 57 82 25 00</phone>
      <email>marie.beylot-barry@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christine ALFARO</last_name>
      <phone>+335 56 82 06 55</phone>
      <email>christine.alfaro@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Obre E, Rossignol R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol. 2015 Feb;59:167-81. doi: 10.1016/j.biocel.2014.12.008. Epub 2014 Dec 24. Review.</citation>
    <PMID>25542180</PMID>
  </reference>
  <reference>
    <citation>Hosseini M, Dousset L, Mahfouf W, Serrano-Sanchez M, Redonnet-Vernhet I, Mesli S, Kasraian Z, Obre E, Bonneu M, Claverol S, Vlaski M, Ivanovic Z, Rachidi W, Douki T, Taieb A, Bouzier-Sore AK, Rossignol R, Rezvani HR. Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation. Cell Rep. 2018 Jun 19;23(12):3621-3634. doi: 10.1016/j.celrep.2018.05.060.</citation>
    <PMID>29925003</PMID>
  </reference>
  <reference>
    <citation>Hosseini M, Dousset L, Michon P, Mahfouf W, Muzotte E, Bergeron V, Bortolotto D, Rossignol R, Moisan F, Taieb A, Bouzier-Sore AK, Rezvani HR. UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis. Oncogenesis. 2019 Sep 24;8(10):52. doi: 10.1038/s41389-019-0161-z.</citation>
    <PMID>31551419</PMID>
  </reference>
  <reference>
    <citation>Mahfouf W, Hosseini M, Muzotte E, Serrano-Sanchez M, Dousset L, Moisan F, Rachidi W, Taieb A, Rudolf J, Rezvani HR. Loss of Epidermal HIF-1α Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress. J Invest Dermatol. 2019 Sep;139(9):2016-2028.e7. doi: 10.1016/j.jid.2019.01.035. Epub 2019 Mar 13.</citation>
    <PMID>30878676</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic keratosis</keyword>
  <keyword>mitochondria</keyword>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

